| Active substance |
Regorafenib |
| Also known as |
BAY 73-4506 |
| Blood pressure |
Can cause hypertension |
| Chemical name |
4-(4-((4-(2-(Methylcarbamoyl)pyridin-4-yl)oxy)phenylamino)phthalazin-1-yl)-3-fluorobenzenesulfonamide |
| Dosage (medical) |
Typically 160 mg taken orally once daily for the first 3 weeks of a 4-week cycle |
| Dosage (sports) |
Not applicable as it is not used for sports enhancement |
| Effects |
Inhibits tumor growth and reduces tumor vascularization |
| Formula |
C21H15ClF4N4O3 |
| Half-life |
Approximately 28 hours |
| Hepatotoxicity |
Yes, can cause elevated liver enzymes and hepatotoxicity |
| Lab Test |
Monitoring of liver function and blood counts is recommended |
| Main action |
Targets and inhibits tumor angiogenesis, oncogenesis, and the tumor microenvironment |
| Side effects |
Hand-foot skin reactions, diarrhea, fatigue, hypertension, rash, decreased appetite, and infection |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Strength |
40mg |
| Substance class |
Kinase inhibitor |
| Trade name |
Stivarga |
| Use in sports |
None, as it is not an enhancing drug |
| Water Retention |
Minimal |
| Manufacturer |
Natco Pharmaceuticals Ltd. |
| Packing |
28 tabs/bottle |
